Navigation Links
Rempex Announces Series B Financing of Up to $67.5 Million

SAN DIEGO, Nov. 9, 2011 /PRNewswire/ -- Rempex Pharmaceuticals, Inc. today announced that it has completed the initial closing of a Series B financing.  New investors Frazier Healthcare Ventures and Vivo Ventures joined existing investors SV Life Sciences, OrbiMed Advisors and Adams Street Partners in committing to a total of $67.5 million for this round.  This financing, together with a previous Series A round, brings the total financing commitment for Rempex to $76 million since the company's founding in June 2011.

Rempex is focused on developing internally discovered new treatments for resistant gram-negative infections.  The company expects to file a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for its first product candidate in the second half of 2012 and an Investigational New Drug Application (IND) with the FDA for its second product candidate in the first quarter of 2012.

"We are very pleased to have been able to attract such a strong group of experienced healthcare investors," stated Daniel Burgess, President and Chief Executive Officer of Rempex.  "This financing gives us the resources to rapidly advance our development programs towards commercialization at a time when the need for new treatments for resistant gram-negative infections has become critical."

About Rempex Pharmaceuticals

Rempex Pharmaceuticals, Inc. is a biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. The company was founded to acquire all the assets, including financial and human resources, not associated with Aeroquin™ from Mpex Pharmaceuticals, Inc.  Aptalis Holdings Inc. acquired Mpex and its lead product candidate, Aeroquin™, earlier this year.  Company website:

SOURCE Rempex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Amylin Pharmaceuticals Announces Date and Time Change to Previously Announced Presentation at the Credit Suisse 2011 Healthcare Conference
2. NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinsons Disease
3. China Sky One Medical Announces Third Quarter 2011 Results
4. China Information Technology, Inc. Announces Third Quarter 2011 Results
5. Uroplasty Announces Issuance of New Apparatus Patent for the Urgent® PC Neuromodulation System Stimulator
6. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
7. K-V Pharmaceutical Announces Updated Makena® Performance Metrics
8. MedBox Announces Ticker Symbol Change
9. SMT Research & Development, Ltd. Names Shuki Porath as Vice President and General Manager, Announces TCT Presence
10. ECRI Institute Announces its Top 10 Health Technology Hazards for 2012
11. Echo Therapeutics Announces Third Quarter 2011 Financial Results
Post Your Comments:
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... On Tuesday, November 24, 2015, the ... Wright Medical Technology, Inc. for product liability and ... implant device, awarded $11 million in favor of ... and three days of deliberations, the jury found ... designed and unreasonably dangerous, and that Wright Medical ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... the way that they are handling security in light of the recent terrorist attacks ... in an attempt to stop an attack from reaching U.S. soil. Especially around special ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss ... to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When ... said an inventor from Hillside, N.J. "Many people catch diseases simply from sitting ... individuals will always be protected from germs." , He developed the patent-pending QUDRATECS ...
(Date:11/27/2015)... ... ... The print component of “Supporting Our Caregivers” is distributed ... Minneapolis, South Florida, with a circulation of approximately 250,000 copies and an estimated ... media strategy and across a network of top news sites and partner media ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
Breaking Medicine News(10 mins):